AI assistant
MACROGENICS INC — Director's Dealing 2024
Mar 6, 2024
34129_dirs_2024-03-06_1ebf4fb0-de77-4dd3-8fa1-fe27728e3429.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: MACROGENICS INC (MGNX)
CIK: 0001125345
Period of Report: 2024-03-04
Reporting Person: Risser Eric Blasius (Chief Operating Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-03-04 | Common Stock | M | 15000 | $10.15 | Acquired | 80059 | Direct |
| 2024-03-04 | Common Stock | S | 15000 | $20 | Disposed | 65059 | Direct |
| 2024-03-04 | Common Stock | S | 26159 | $19.63 | Disposed | 38900 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-03-04 | Employee stock option (right to buy) | $10.15 | M | 15000 | Disposed | 2032-02-22 | Common Stock (15000) | Direct |
Footnotes
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/21/2022.
F2: This transaction was executed in multiple trades at prices ranging from $19.50 to $19.78. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter.